CytomX Therapeutics Ownership | Who Owns CytomX Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

CytomX Therapeutics Ownership Summary


CytomX Therapeutics is owned by 16.90% institutional investors, 0.59% insiders, and 82.51% retail investors. Fmr is the largest institutional shareholder, holding 18.78% of CTMX shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.07% of its assets in CytomX Therapeutics shares.

CTMX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCytomX Therapeutics16.90%0.59%82.51%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr31.96M18.78%$150.19M
Kynam capital management, lp15.01M8.82%$70.56M
Tang capital management11.07M8.57%$35.30M
Perceptive advisors10.10M5.93%$47.46M
Vr adviser9.98M5.87%$46.92M
Vanguard group8.48M5.14%$36.11M
Point72 asset management7.88M4.63%$37.01M
State street5.66M3.33%$26.62M
Citadel advisors5.41M3.18%$25.41M
Adar1 capital management4.05M3.13%$12.90M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp15.01M4.35%$70.56M
Vr adviser9.98M1.75%$46.92M
Velan capital investment management lp540.00K1.59%$2.54M
Nextech invest4.45M1.47%$20.91M
Tang capital management11.07M1.36%$35.30M
Exome asset management521.47K1.27%$2.45M
Adar1 capital management4.05M1.21%$12.90M
Perceptive advisors10.10M0.93%$47.46M
Schulhoff477.55K0.92%$2.24M
Patient square capital lp1.09M0.91%$5.10M

Top Buyers

HolderShares% AssetsChange
Fmr31.96M0.01%7.27M
Kynam capital management, lp15.01M4.35%6.05M
Citadel advisors5.41M0.00%5.06M
Nextech invest4.45M1.47%4.45M
Wellington management group llp3.58M0.00%3.58M

Top Sellers

HolderShares% AssetsChange
Commodore capital lp---7.69M
Franklin resources---5.77M
Vr adviser9.98M1.75%-5.58M
Bvf inc/il---5.23M
Fairmount funds management---3.90M

New Positions

HolderShares% AssetsChangeValue
Nextech invest4.45M1.47%4.45M$20.91M
Wellington management group llp3.58M0.00%3.58M$16.84M
Siren3.46M0.45%3.46M$16.25M
Gilder gagnon howe1.12M0.06%1.12M$5.27M
Vanguard fiduciary trust1.10M0.00%1.10M$5.18M

Sold Out

HolderChange
Innealta capital-2.00
Old point trust & financial services n a-250.00
Raleigh capital management-250.00
Bell investment advisors-388.00
Federated hermes-398.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202660-53.85%23,309,564-83.82%160.22%40-48.05%11-59.26%
Dec 31, 202570-37.50%44,567,168-67.59%270.39%42-32.26%16-38.46%
Sep 30, 202536-59.09%16,872,803-87.34%130.12%20-64.91%7-58.82%
Jun 30, 20258835.38%133,304,249195.10%1535.69%57128.00%16-36.00%
Mar 31, 202566-7.04%45,273,213-3.09%511.72%26-25.71%2519.05%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF2.46M3.07%-
Vanguard Total Stock Mkt Idx Inv6.53M3.00%-
State Street® SPDR® S&P® Biotech ETF5.03M2.33%-49.67K
Fidelity Select Health Care5.00M2.31%1.60M
Franklin Biotechnology Discv A(acc)USD2.92M1.77%-800.28K
Fidelity Small Cap Growth3.28M1.52%-
Fidelity Select Biotechnology3.10M1.44%1.88M
Fidelity Advisor Health Care I2.50M1.16%750.00K
FIAM Small Cap Core CIT Cl B2.49M1.15%-
FIAM Small Cap Core Composite2.49M1.15%1.40M

Recent Insider Transactions


DateNameRoleActivityValue
Mar 17, 2026Chu Yu-Waye Chief Medical OfficerSell$136.68K
Mar 17, 2026McCarthy Sean A. CEOSell$764.14K
Mar 17, 2026BELVIN MARCIA SVP, Chief Scientific OfficerSell$202.27K
Mar 17, 2026Ogden Christopher Chief Financial OfficerSell$124.11K
Nov 06, 2025McCarthy Sean A. CEOSell$461.91K

Insider Transactions Trends


DateBuySell
2026 Q1-4
2025 Q4-1
2025 Q3--
2025 Q2-4
2025 Q1-5

CTMX Ownership FAQ


Who Owns CytomX Therapeutics?

CytomX Therapeutics shareholders are primarily institutional investors at 16.90%, followed by 0.59% insiders and 82.51% retail investors. The average institutional ownership in CytomX Therapeutics's industry, Biotech Stocks , is 35.75%, which CytomX Therapeutics falls below.

Who owns the most shares of CytomX Therapeutics?

CytomX Therapeutics’s largest shareholders are Fmr (31.96M shares, 18.78%), Kynam capital management, lp (15.01M shares, 8.82%), and Tang capital management (11.07M shares, 8.57%). Together, they hold 36.17% of CytomX Therapeutics’s total shares outstanding.

Does Blackrock own CytomX Therapeutics?

BlackRock is not among the top 10 institutional shareholders of CytomX Therapeutics.

Who is CytomX Therapeutics’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is CytomX Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.35% of its assets in 15.01M CytomX Therapeutics shares, valued at 70.56M$.

Who is the top mutual fund holder of CytomX Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of CytomX Therapeutics shares, with 3.07% of its total shares outstanding invested in 2.46M CytomX Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools